Polatuzumab vedotin with rituximab and chidamide for older adults with double-expressor DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs for newly diagnosed older adults with a specific type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this treatment is safe and effective for patients who may not be able to tolerate standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 70 years old, or between 60 and 69 with some health frailty.
- You have been diagnosed with double-expressor diffuse large B-cell lymphoma (DLBCL) that is not the double-hit or triple-hit type.
- You have at least one tumor that can be measured or seen on scans.
- You have not received any prior treatment for your lymphoma.
- Your major organs and bone marrow are working well enough.
- You do not have lymphoma in your brain or spinal cord, or certain active infections like HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new Double Expressor DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.